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INTRODUCTION 
 
Diabetes mellitus which is now being termed as an epidemic is spiraling upwards at an alarming 
rate, raising worldwide concern about its devastating effects on health and healthcare systems. It 
is estimated that presently there are 200 million diabetics and it is expected to reach 360 million 
by 2030 as per World Health Organization projections, with the largest number of cases going to 
be seen in China, India and USA. More than 90% of these are likely to be type 2 diabetes (DM) 
individuals.   
In recent years with the explosion of knowledge and the sound pathophysiological basis, the 
distinction between the type2 diabetes and the cardiovascular disease has been blurred, and the 
central importance of Cardio Vascular Disease (CVD) prevention is becoming an integral part of 
DM management. 
T2DM carries an equivalent cardio vascular risk to that of non diabetic individual who already 
experienced a coronary event 
(1)
. DECODE study 
(2)
 has shown that even before diabetes is 
detected, the person may be predisposed to CVD and these prediabetic levels of blood sugar 
predict mortality. 
A substantial body of evidence supports the concept that the increase risk of morbidity and 
mortality due to CVD is associated with abnormalities in glucose metabolism across the entire 
continuum of glucose tolerance ranging from normal to clinical diabetes 
(1,3) 
Compared with 
patients without diabetes, patients with DM have a 2-4 fold greater risk of death from MI or 
stroke
(3)
. 
 
Diabetes mellitus is an established risk factor for congestive heart failure, but the knowledge of 
the pathophysiology and treatment is limited. The Framingham Heart study has shown that the 
incidence of congestive cardiac failure in diabetic patients occurs irrespective of coronary artery 
disease or hypertension 
(3)
.  
In overt heart failure, diastolic dysfunction often co-exists with systolic dysfunction as a 
consequence of  ischemic  heart disease, but diastolic  dysfunction is a frequent  finding in type 2 
diabetes mellitus without signs and symptoms of heart disease and is presumably due to diabetic  
cardiomyopathy. Left   ventricular diastolic function (LVDF) is affected earlier than systolic 
function in the development of congestive cardiac failure 
(4)
. 
Therefore  left ventricular diastolic dysfunction may  represent the first stage of diabetic 
cardiomyopathy, thus an  early  examination of  left ventricular diastolic function may help to 
detect this condition in patients with diabetes, thereby allowing early intervention for a more 
favorable  outcome
(5)
.             
This study was done to understand the burden of left ventricular diastolic dysfunction (LVDD) in 
patients with newly diagnosed type 2 diabetes and to assess the risk factors for the development 
of diastolic dysfunction in such patients. 
 
                     
 
 
 
AIM OF THE STUDY 
 
 To assess the effect of isolated type 2 diabetes on left ventricular systolic and diastolic 
functional reserve. 
  
 To assess the risk factor associated with heart failure in diabetic patients. 
 
 To compare this prevalence to that of age and sex matched asymptomatic control   
population. 
  
                         
                   REVIEW OF LITERATURE 
Diabetes Mellitus refers to a group of common metabolic disorders that share the phenotype of 
hyperglycemia. Several distinct types of DM exist and are caused by a complex interaction of 
genetics and environmental factors. 
 
 HISTORY 
The first documented evidence of diabetes mellitus was reported in Egyptian papyrus, as a 
polyuric state. In 1776 Mathew Dobson established the presence of sugar in blood and urine of 
diabetic patients. Type 2 diabetes is the commonest form of diabetes in any country. 
 
EPIDEMIOLOGY 
The global evidence of diabetes is estimated to increase from 4% in 1995 to 5.4% by the year 
2025. Considerable geographic variation is seen, with most of the cases from India, USA, and  
Europe. India has the dubious distinction of having the  highest  number of diabetes in the 
world.The prevalence in India varies from 1.7 to 9.6% in various studies. A multicenter study 
done by India Council of Medical Research showed a prevalence rate of 1.73 percent in Indians 
above 15 yrs of age. According to Prevalence Of  Diabetes in India Study(PODIs) the prevalence 
of type 2 diabetes in India is urban-9.6% rural-4.2% .   
 
 
 
AETIOLOGY OF DIABETES MELLITUS 
Type I diabetes mellitus 
1. Genetics:  
Genetic predisposition is possible permissive and not casual. Risk of diabetes is up to 5 times 
higher when the father is diabetic rather than mother. This risk is limited to father carrying an 
HLA DR4 susceptibility gene. 
Risks for identical twin is 33%. Genetic loci - Chromosome 6 
2. Viruses 
20% of persons with congenital rubella develop IDDM. Cytomegalovirus is present in 
genome of 20% patients. Others implicated are Coxsackie, Mumps and hepatitis. 
3. Diet 
Introduction of cow’s milk before the age of 2 – 3 months is associated with an increased 
risk. 
4. Pancreatic pathology 
Insulitis 
TYPE II DIABETES MELLITUS 
Genetics :  
Probably polygenic 
The role of genetic factors in the etiology of type 2 DM has been appreciated ever since the 
recognition of the disease. There is almost 100% concordance in monozygotic twins. Maturity 
onset diabetes may be associated with a mutation of glucokinase gene. 
 
 
Life style 
Over eating; especially combined with obesity and under activity, leads to diabetes 
mellitus. 
Age 
It is principally a disease of middle aged and elderly 
Pregnancy 
80% of women with gestational diabetes develop permanent diabetes requiring treatment 
later in life. 
Insulin resistance 
There is increased hepatic glucose production and resistance to the action of insulin in 
muscle. 
ETIOLOGIC CLASSIFICATION OF DIABETES MELLITUS 
1. Type 1 diabetes (β-cell destruction, usually leading to absolute insulin deficiency) 
 
A. Immune – mediated 
B. Idiopathic 
 
2. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin 
deficiency to a predominantly insulin secretory defect with insulin resistance) 
 
3. Other specific types of diabetes 
A. Genetic defects of β-cell function characterized by mutations in:    
a. Hepatocyte nuclear transcription factor (HNF) 4 α (MODY 1) 
b. Glucokinase (MODY 2) 
c. HNF – 1 α (MODY 3) 
d. Insulin promoter factor (IPF) 1 (MODY 4) 
e. HNF – 1 β (MODY 5) 
f. Mitochondrial DNA 
g. Proinsulin or insulin conversion 
 
B. Genetic defects in insulin action 
a. Type A insulin resistance 
b. Leprechaunism 
c. Rabson – Mendenhall syndrome 
d. Lipoartrophic diabetes 
 
C. Disease of the exocrine pancreas – pancreatitis, pancreatectomy, neoplasia, 
     cystic fibrosis, hemochromatosis, fibrocalculous pancreatopathy. 
 
D. Endocrinopathies – acromegaly, Cushing’s syndrome, glucagonoma, 
    pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma. 
 
E.  Drug or chemical induced – Vacor, pentamidine,  
     nicotinic     acid,glucocorticoids,   thyroid hormone, diazoxide,  
     β-adrenergic  agonists, thiazides,phenytoin, α- interferon, 
     protease inhibitors, clozapine, and beta-blockers. 
 
F. Infections – congenital rubella, cytomegalovirus, Coxsackie 
 
G.  Uncommon forms of immune mediated diabetes –  
     ―stiff-man‖ syndrome,  antiinsulin receptor antibodies. 
 
H. Other genetic syndromes sometimes associated with diabetes – Down’s 
     syndrome, Klinefelter’s syndrome, Turner’s syndrome, Wolfram’s syndrome, 
     Friedreich’s ataxia, Huntington chorea, Laurence – Moon –Biedl syndrome,  
     myotonic dystrophy, porphyria, Prader-Willi syndrome.   
  4. Gestational diabetes mellitus (GDM). 
RISK FACTORS FOR TYPE 2 DIABETES MELLITUS 
a.  Family history of diabetes (i.e. parent or sibling with type 2 diabetes) 
b. Obesity (i.e. > 20% desired body weight or BMI > 25 kg/m2) 
c.  Age > 45 years 
d. Race/ethnicity (e.g. African, American, Hispanic American, Native American, Asian 
American, Pacific Islander) 
e. Previously identified IFG or IGT 
f. History of GDM or delivery of baby over 9 pounds. 
g.  Hypertension (blood pressure > 140/90 mm Hg) 
h. HDL cholesterol level < 0.90 mmol/L (35 mg/dL) and / or a triglyceride level 2.82 
mmol/L (250 mg/dL) 
i.  Polycystic ovary syndrome 
STAGES OF DIABETES 
 
Stages of diabetes range from normal glucose tolerance, through IGT and IFG (impaired fasting 
glucose), into frank diabetes mellitus, which may be non-insulin requiring, insulin requiring for 
control and insulin requiring for survival.  
Type 1 DM can be found across the whole spectrum. In the early stages of treatment there can be 
a period of non-insulin requirement, but later followed by insulin requirement for survival. In 
type 2 DM, insulin may be required during a period of  ketoacidosis precipitated by severe stress 
or infection. 
 
Diabetes and heart 
Patients with diabetes mellitus are at increased risk for cardiovascular diseases. Thus, 
cardiovascular complications are the leading cause of diabetes-related morbidity and mortality
(2)
. 
The American Heart Association recently designed DM as a major risk factor for cardiovascular 
disease (same category as smoking hypertension and hyperlipidaemia). Type 2 diabetic patient 
without a prior M1 have a similar risk for coronary artery related events as non-diabetic 
individuals who have had a prior myocardial infarction
(3)
. 
The main factor that contribute to the increased incidence of cardiovascular disease in diabetic 
patients are 
1. The acceleration of atherosclerotic process leading to macrovascular disease. 
2. Development of specific cardiomyopathy. 
3. Progressive microvascular disease. 
4. Development of autonomic neuropathy. 
 
Heart failure 
Heart failure is a complex clinical syndrome manifesting as the inability of the heart to fill with 
or eject blood due to any structural or functional cardiac conditions.
 
 Heart failure can be broadly 
classified into Systolic Heart Failure or Heart Failure With Reduced Ejection Fraction (HFREF) 
and Heart Failure with Normal Ejection Fraction (HFNEF) also earlier known as Diastolic Heart 
Failure. There can also be a combination of both. 
Systolic heart failure 
 
Heart failure caused by systolic dysfunction is more readily recognized. It can be described as 
impaired contractile or pump function of the heart. It is characterized by a decreased ejection 
fraction (less than 45%). The strength of ventricular contraction is attenuated and inadequate for 
creating an adequate stroke volume, resulting in inadequate cardiac output. In general, this is 
caused by dysfunction or destruction of cardiac myocytes or their molecular components.  
Diastolic heart failure 
Diastolic heart failure,  is defined as symptoms of heart failure in a patient with preserved left 
ventricular function. It is characterized by a stiff left ventricle with decreased compliance and 
impaired relaxation, which leads to increased end diastolic pressure. Signs and symptoms are 
similar to those of heart failure with systolic dysfunction. 
Pathophysiology of diastolic heart failure 
(7)
 
Diastole is the process by which the heart returns to its relaxed state; it is also the time for 
cardiac perfusion. During diastole, drastic changes in cardiac pressure-volume relationships 
occur. The relaxation process has four identifiable phases: isovolumetric relaxation from the time 
of aortic valve closure to mitral valve opening; early rapid filling after mitral valve opening; 
diastasis, a period of low flow during mid-diastole; and late filling of the ventricles from atrial 
contraction ( Figure 1). 
 
 
Figure 1.Cardiac cycle, showing changes in left atrial pressure, left ventricular pressure, aortic 
pressure, and ventricular volume; the electrocardiogram (ECG); and the phonocardiogram. 
 
In patients with isolated diastolic heart failure, the heart often is able to meet the body's 
metabolic needs, but at higher diastolic pressures. The left ventricle is stiff, with decreased 
compliance and impaired relaxation. Transmission of the higher end-diastolic left ventricular 
pressure to the pulmonary circulation may lead to pulmonary congestion, dyspnea, and other 
symptoms of heart failure. 
Diastole is a complex process that is affected by a number of factors, including ischemia, heart 
rate, velocity of relaxation, cardiac compliance (i.e., elastic recoil and stiffness), hypertrophy, 
and segmental wall coordination of the heart muscle 
Heart failure in diabetes 
Diabetes accounted for a significant percentage of patients with a diagnosis of heart failure in 
numerous epidemiologic studies. The Framingham Study,
3
 United Kingdom Prospective 
Diabetes Study,
8 
Cardiovascular Health Study, and Euro Heart Failure Surveys all suggested that 
the presence of diabetes may independently increase the risk of developing incident heart failure. 
 
The etiology of this abnormality is probably multi factorial and includes factors such as 
myocardial ischaemia from atherosclerosis, hypertension and myocardial dysfunction secondary 
to chronic hyperglycemia. 
 
The mechanisms of HF in diabetic patients 
 
Figure 3 illustrates the varies mechanism of heart failure in diabetes mellitus. DM may be 
causally related to HF development by at least 3 mechanisms:  
1. Due to associated comorbidities,  
2. By favoring the development of coronary atherosclerosis,   
3. Through a specific diabetic cardiomyopathy. 
                      
             
 Figure. 2 Potential mechanisms linking diabetes mellitus to heart failure. 
 
 
Potential mechanisms linking diabetes mellitus to heart failure: Diabetes mellitus is associated with multiple 
physiopathological changes in the cardiovascular system. Among these, endothelial dysfunction and hemostatic 
disorders may at least in part account for the higher risk of coronary artery disease (CAD) while microangiopathy, 
myocardial fibrosis, and abnormal myocardial metabolism have been implicated in the pathogenesis of a specific 
diabetic cardiomyopathy.  
When it occurs in diabetic patients, heart failure (HF) is, in most cases, a consequence of CAD; other possible 
causes include the comorbidities frequently encountered in diabetic patients such as hypertension, or other causes of 
nonischemic cardiomyopathy. The existence of a diabetic cardiomyopathy may increase the risk of HF in response 
to these insults; however, whether diabetic cardiomyopathy alone may be responsible for HF remains unknown.  
Diabetic cardiomyopathy  
Diabetic cardiomyopathy has been defined as the presence of myocardial abnormalities in the 
absence of coronary artery disease, hypertension or other significant etiology
(3)
. Hyperglycemia 
seems to be central to the pathogenesis of diabetic cardiomyopathy and to trigger a series of 
maladaptive stimuli that result in myocardial fibrosis and collagen deposition. These processes 
are thought to be responsible for altered myocardial relaxation characteristics and manifest as 
diastolic dysfunction on imaging 
(9)
. 
                  
Pathogenesis of Diabetic Cardiomyopathy:  
Mechanisms
(10)
 
The pathogenesis of diabetic cardiomyopathy is multifactorial. Several hypotheses have been 
proposed, including autonomic dysfunction, metabolic derangements, abnormalities in ion 
homeostasis, alteration in structural proteins, and interstitial fibrosis
(11,12)
  Sustained  
hyperglycemia also may increase glycation of interstitial proteins such as collagen, Interstitial 
accumulation of advanced-glycated end products (AGEs), which results in myocardial stiffness 
and impaired contractility
(13–15)
 
Several  mechanisms that are involved in decreasing myocardial contractility in diabetes 
mellitus. These are 
 (1) Impaired calcium homeostasis,  
(2) Upregulation of the renin-angiotensin system,  
(3) Increased oxidative stress,  
(4) Altered substrate metabolism, and 
 (5) Mitochondrial dysfunction. 
 Impaired calcium homeostasis 
The mechanisms by which disturbed calcium homeostasis alters cardiac function in diabetes 
include reduced activity of ATPases
,(16)
 decreased ability of the SR to take up calcium, and 
reduced activities of other exchangers such as Na
+
-Ca
2+
 and the sarcolemmal Ca
2+
ATPase.
(17,18). 
Furthermore, decreased cardiac expression of SERCA2a or the Na
+
Ca
2+
 - exchanger has been  
observed in type 1
(10)
 and type 2 diabetes
.(20).
 Trost et al
( 21)
 observed that transgenic mice 
overexpressing SERCA2a were protected from streptozotocin-induced cardiac dysfunction, 
suggesting that altered calcium handling contributes to impaired cardiac function in diabetes 
mellitus. 
Activation of the Renin-Angiotensin System 
The role of activation of the renin-angiotensin system in the development of diabetic 
cardiomyopathy is well recognized
.(22)
 Angiotensin II receptor density and mRNA expression are 
elevated in the diabetic heart
.(23–25)
 Activation of the renin-angiotensin system during diabetes 
mellitus has been shown to be associated with increased oxidative damage and cardiomyocyte 
and endothelial cell apoptosis and necrosis in diabetic hearts, 
(26)
 which contributes to the 
increased interstitial fibrosis. 
Increased Oxidative Stress 
Increased reactive oxygen species (ROS) production in the diabetic heart is a contributing factor 
in the development and the progression of diabetic cardiomyopathy
(27,28)
 Several groups have 
shown that ROS is overproduced in both type 1 and type 2 diabetes.
29,30
 Increased ROS 
generation may activate maladaptive signaling pathways, which may lead to cell death, which 
could contribute to the pathogenesis of diabetic cardiomyopathy.
31
 Thus, increased ROS-
mediated cell death could promote abnormal cardiac remodeling, which ultimately may 
contribute to the characteristic morphological and functional abnormalities that are associated 
with diabetic cardiomyopathy. 
In addition to causing cellular injury, increased ROS production might lead to cardiac 
dysfunction via other mechanisms. For example, increased ROS has been proposed to amplify 
hyperglycemia-induced activation of protein kinase C isoforms, increased formation of glucose-
derived advanced glycation end products, and increased glucose flux through the aldose 
reductase pathways,
32,33
 which may all contribute in various ways to the development of cardiac 
complications in diabetes mellitus. Thus, strategies that either reduce ROS or augment 
myocardial antioxidant defense mechanisms might have therapeutic efficacy in improving 
myocardial function in diabetes mellitus. 
Altered Substrate Metabolism 
Altered myocardial substrate and energy metabolism has emerged as an important contributor to 
the development of diabetic cardiomyopathy.
34,35
. Diabetes mellitus is characterized by reduced 
glucose and lactate metabolism and enhanced fatty acid (FA) metabolism.
36,37
 Despite an 
increase in FA use in diabetic hearts, it is likely that FA uptake exceeds oxidation rates in the 
heart, thereby resulting in lipid accumulation in the myocardium that may promote 
lipotoxicity
(38-40)
. Lipid intermediates such as ceramide might promote apoptosis of 
cardiomyocytes, thus representing another mechanism that might lead to cardiac dysfunction.
41
 
 
Free Fatty Acid Metabolism Disturbances 
Figure 3 summarizes the role of altered free fatty acid metabolism and its contribution to the 
development of diabetic cardiomyopathy. Figure 4 illustrates the role of hyperglycemia in 
inducing the ultimate downstream effects. In the absence of diabetes, approximately equivalent 
proportions of energy required for cardiac contractility come from glucose metabolism and free 
fatty acids; whereas in diabetes, myocardial glucose use is significantly reduced, with a shift in 
energy production from beta-oxidation of free fatty acids.
42
 This reduction in glucose use in the 
diabetic myocardium results from depleted glucose transporter proteins, glucose transporter-1 
and 4. In addition, free fatty acids inhibit pyruvate dehydrogenase, which impairs myocardial 
energyproduction and leads to the accumulation of glycolytic intermediates and ceramide, 
enhancing apoptosis.
43,44
 In addition to the effects of free fatty acids on glucose metabolism 
and oxidative phosphorylation, free fatty acid metabolism for adenosine triphosphate production 
requires large amounts of oxygen. The toxic intermediates resulting from free fatty acid 
metabolism
(42,45)
 (so-called lipotoxicity) can impair myocyte calcium handling, worsening 
myocardial mechanics.
46-48
 
 
Figure 3 Overall schema for the pathogenesis of diabetic cardiomyopathy. 
FFA-free fatty acid; CPC-cardiac progenitor cells; RAAS-renin-angiotensin-aldosterone system 
 
 Figure 4 Effects of hyperglycemia on the diabetic myocardium. 
 
Mitochondrial Dysfunction 
Recent studies of mitochondria have reignited interest in a role for mitochondrial dysfunction in 
the pathogenesis of diabetic cardiomyopathy.
49-51
 Diabetes mellitus causes functional and 
structural alterations in mitochondria. 
Impaired mitochondrial function was initially reported almost 25 years ago when Kuo et al 
showed depressed state 3 respiration in db/db heart mitochondria. This study was followed by 
others showing reduced mitochondrial oxidative capacity in type 1 diabetes.
52–55
 
 
Boudina et al demonstrated decreased mitochondrial respiration and reduced protein expression 
of the oxidative phosphorylation components in obese type 2 diabetic mice.
49
 These alterations 
contribute to cardiac dysfunction because they reduce ATP production, which we speculate will 
diminish myocardial high-energy phosphate reserves, thereby contributing to impaired 
myocardial contractility. 
 
Autonomic Neuropathy 
Diabetic autonomic neuropathy can lead to changes in sympathetic innervations and subsequent 
disordered adrenergic receptor expression and altered catecholamine levels in the myocardium. 
An increased expression of theβ1-receptor results in enhanced apoptosis, fibrosis, hypertrophy, 
and impaired myocardial function.
56  
 
DIAGNOSING DIABETIC CARDIOMYOPATHY 
There are 2 important components in the clinical diagnosis of diabetic  cardiomyopathy: the 
detection of myocardial abnormalities and the exclusion of other  contributory causes of 
cardiomyopathy.  
         
An important challenge in the clinical diagnosis of diabetic cardiomyopathy has  been the lack of 
any pathognomonic histologic changes or imaging characteristics  associated with the diagnosis. 
Endomyocardial biopsies are not indicated because of  their invasiveness, unless circumstances 
to suspect other causes of cardiomyopathy in the differential diagnosis exist (eg, hypertrophic 
cardiomyopathy and infiltrative heart diseases).Nevertheless, the presence of myocardial fibrosis 
or collagen deposition can be fairly characteristic of diabetic cardiomyopathy. Electron 
microscopic features, including mitochondrial abnormalities, fatty acid deposits, or even 
myocyte hypertrophy, can be evident. 
 
The diagnosis of diabetic cardiomyopathy currently rests on noninvasive imaging techniques that 
can demonstrate myocardial dysfunction across the spectra of clinical presentation. There is still 
no consensus in the precise imaging definition of diabetic  cardiomyopathy, but evidence of 
hypertrophy or diastolic dysfunction is likely crucial to support a diagnosis of diabetic 
cardiomyopathy, but is not specific to it. 
 
On the basis of the review of the literature, the imaging definition of diabetic cardiomyopathy 
that includes either or both features listed as follows: 
 
● Evidence of cardiac hypertrophy determined by conventional echocardiography or cardiac 
magnetic resonance imaging; 
 
● Evidence of LV diastolic dysfunction (with or without LV systolic dysfunction), either 
clinically by transmitral Doppler or tissue Doppler imaging (TDI), or evidence of left atrial 
enlargement; or subclinically by novel imaging techniques or provocative testing (eg,  strain rate 
imaging or stress imaging). 
 
 
 
 
Methods of diagnosing diastolic dysfunction 
 
Cardiac catheterisation with simultaneous pressure and volume measurements is the ―gold 
standard‖ for assessing LV diastolic function. The rate of LV relaxation, rate and timing of 
diastolic filling as well as myocardial and chamber stiffness can be determined 
[57]
. However, this 
diagnostic method is invasive and cannot be performed in all patients with suspected diastolic 
dysfunction. 
 
During the last two decades, Doppler echocardiography has emerged as an important and easy to 
perform noninvasive diagnostic tool providing reliable data on diastolic performance. The trans-
mitral flow across the mitral valve demonstrates a biphasic pattern, in which an early peak flow 
occurs during rapid early diastolic filling (peak E) and a late peak occurs during atrial 
contraction (peak A).Based on Doppler trans mitral flow, a grading system for diastolic 
dysfunction has been proposed. 
 
Three characteristic abnormal LV diastolic filling patterns mainly based on the E/A ratio have 
been proposed 
[58]
  
 The first abnormal filling pattern, called ―delayed relaxation‖, results in a reversed E/A 
ratio (E/A < 1) when relaxation impairs. It identifies patients with early stages of heart 
disease.  
 The second pattern, representing abnormalities of both relaxation and compliance, has 
been termed  pseudo normalization, because of an apparently normal E/A ratio (E/A > 1). 
This results from an increase in left atrial pressure compensating for slow relaxation.  
 The third abnormal filling pattern, termed ―restrictive filling‖, found in patients with 
severe decrease in LV com pliance, causes an increased E/A ratio (often above 2). It 
identifies advanced, usually symptomatic disease with poor prognosis. 
 
Other Doppler derived indices have been proposed, of which deceleration time (the time interval 
of peak E wave velocity to zero), and isovolumic relaxation time (time from the end of systolic 
ventricular outflow to mitral valve opening) are applied most often. 
 
 
 
 
 
 
 
 
 
 
 Normal trans–mitral-valve spectral Doppler flow pattern. The E-to-A-wave ratio is pproximately 
1.4 to 1.0. 
 
Trans–mitral-valve Doppler flow tracing in a patient with mild diastolic dysfunction (abnormal 
relaxation). The E-to-A-wave ratio is less than 1.0. 
 
Trans–mitral-valve Doppler flow pattern in a patient with severe (restrictive) diastolic 
dysfunction. The E-to-A-wave ratio is abnormally high, and the A-wave velocity is extremely 
low. 
 LEFT VENTRICULAR FUNCTION IN DIABETES MELLITUS 
 
Numerous studies have shown that impairment of the LV diastolic function may be detected in 
patients with diabetes The existence of a diabetic cardiomyopathy was first suggested by Rubler 
et al 
(59)
 in 1972 on the basis of postmortem findings in four adult diabetic subjects with non-
coronary congestive cardiac failure (CCF)  
. 
Subsequent  observations by the Framingham workers about the most frequent occurrence of 
CCF among the diabetics than could be explained by hypertension or ischemic heart disease 
alone, interest was renewed in the field of cardiac involvement in long-standing diabetic patients. 
  
 Regan et al. 
[60]
 demonstrated in normotensive, diabetic patients without coronary artery disease 
and without clinical evidence of heart failure, increased left-ventricular end-diastolic pressure,a 
decreased left-ventricular end-diastolic volume with a normal ejection fraction 
 
 Hamby et al (61) Impaired left ventricular (LV) function may frequently be detected in 
asymptomatic diabetic subjects and is related to the extent of diabetes and evidence of micro 
vascular complications. Although systolic and diastolic functions of the heart are impaired in 
diabetes, many studies have shown that the LV diastolic abnormalities are most common and 
may in fact precede the development, of systolic abnormality. 
 
Thus, diastolic abnormalities present in diabetic patients without diabetic  complications or 
cardiovascular disease has been suggested as an earliest functional effect of a specific diabetic 
cardiomyopathy 
[62, 63]
. 
 
In the large majority of studies, abnormalities of LVdiastolic function have been  demonstrated 
in diabetic patients with intact systolic function Raev et al. 
[64].
 
 
It is now clear from the various studies that the primary functional abnormality in a diabetic heart 
is the impairment of LV diastolic function reflecting the reduced LV filling and that even the 
systolic functional alteration is the result of reduced LV filling. 
 
EVALUATION OF LV FUNCTION IN DIABETIC SUBJECTS 
There are two chief methods of evaluating the LV function 
1. Utilizing the non-invasive techniques. 
2. Invasive techniques 
Non-invasive methods include the assessment by 
a) Systolic time intervals (STI) 
b) Apex cardio graphy (ACG) 
c) Radio nucleotide ventriculography 
d) Echocardiography and cardiac Doppler 
Invasive method is by cardiac catheterization delineating the coronary artery anatomy and LV 
angiography. This procedure is usually reserved for symptomatic diabetic subjects with overt or 
those who manifest CCF and is unnecessary in asymptomatic although long-standing diabetics. 
ECHOCARDIOGRAPHY- M-MODE AND 2-D 
Aerakisnen et al(65) utilizing the digitalized M-mode technique studied 36 female IDDM 
patients with a mean duration of diabetes of 10 years or more and found that the most common 
abnormality (19 pts) was prolonged rapid filling period while the systolic function was normal in 
all. Another study recorded simultaneous echo and phonocardiogram in142diabetics. The LV 
relaxation, the rate and duration of cavity dimension increase and wall thinning were determined. 
Delayed mitral valve opening (MVO) relative to minimal LV cavity dimension and aortic valve 
closure (AVC) was found in all but 12 subjects, especially in those with micro vascular 
complications. Prolongation of isovolumic relaxation time (IVRT) i.e. measured as period 
between AVC and MVO (abnormal, if more than 110 m sec), which can be demonstrated using 
dual M-mode echo preferably at 100 min/sec speed showing simultaneous aortic and mitral valve 
levels, is an important diastolic abnormality, as found by Sanderson et al
(66)
 . 
Others using quantitative cross-sectional echocardiography and stress myocardial perfusion 
scintigraphy found that diabetic subjects had mildly reduced LV end diastolic volumes and 
impaired diastolic filling as assessed by lower left atrial emptying index compared to controls. 
The left atrial emptying index is defined on M-mode tracing of the aorta 
 
DOPPLER TECHNIQUES 
 
Pulsed Doppler ultrasound interrogation of mitral inflow velocities (Doppler cursor placed at the 
tips of the mitral leaflets on apical 4-chamber view) gives a simple and reproducible method of 
determining the LV filling that correlates well with radio nucleotide and invasive techniques. 
Ventricular filling in the normal subjects is characterized by a biphasic pattern with an initial 
peak velocity of rapid early ventricular filling ('E') and a relatively low peak velocity of late 
inflow due to atrial contraction (A). Impaired diastolic filling of the left ventricle in both Type 1 
and Type 2 asymptomatic diabetics without the evidence of cardiovascular disease and unrelated 
to microangiopathic complications has been demonstrated using PW Doppler which showed 
reduction in the early filling velocity (reduced 'E' peak) and compensatory increase in the late 
flow (increased 'A' peak) and thus increased A/E ratio (i.e. A/E more than 1). Besides, the 
deceleration of 'E' velocity is prolonged indicating a slow rapid-filling phase ('E' deceleration 
more than 250 m/sec). Increased atrial contribution to LV filling can be assessed by the area 
under the late diastolic filling envelope compared to the total diastolic area. Various studies have 
demonstrated these above Doppler findings in young diabetic subjects without evidence of heart 
failure. 
 
A 3-year follow-up study by Charella et al of a group of asymptomatic diabetics with slow filling 
and wall thinning demonstrable on echocardiography showed 31% developing heart failure and 
19% that died. Measurement of LV diastolic function may therefore prove to be a useful 
indicator of cardiovascular morbidity and mortality in diabetics. 
Hence abnormal diastolic function suggestive of reduced LV compliance resulting in a 'Stiff' 
myocardium appears to be the hall mark of the specific type of diabetic heart muscle disease. 
The presence or addition of hypertension or coronary artery disease will certainly put a new 
burden on the already 'non-compliant’ myocardium in long-standing diabetics with or without 
micro vascular complications. 
 
 
 
 ECHO PICTURE OF M-MODE SHOWING VARIOUS LV DIMENSIONS 
 
 
 
 
 
 DOPPLER ECHO SHOWING GRADING OF DIASTOLIC DYSFUNCTION 
 
 
 
 
 
PREVENTION AND THERAPY 
Glycemic Control 
The prevention and treatment of diabetic cardiomyopathy are clinically relevant because of its 
role in the pathogenesis of heart failure. Although the effect of glycemic control on diabetic 
cardiomyopathy has been studied in only a limited fashion, evidence suggests that good glycemic 
control is beneficial, at least in the early stages of myocardial dysfunction 
(67-69)
. Evidence also 
suggests that diabetic cardiomyopathy does not develop in patients with tightly controlled type 1 
diabetes, supporting an important role for hyperglycemia in the pathogenesis of diabetic 
cardiomyopathy
70
. Hyperglycemia is responsible for microvascular complications in diabetes, 
and because microvascular alterations are thought to contribute significantly to the pathogenesis 
of diabetic cardiomyopathy, good glycemic control is perhaps the most important component in 
the overall management of diabetic cardiomyopathy. Firm recommendations regarding the 
choice of current glucose-lowering therapies in patients with diabetic cardiomyopathy cannot be 
made because of a lack of evidence. 
 
However, glucagon-like peptide-1 analogues have demonstrated improved hemodynamic 
variables in diabetic patients without overt heart failure. Improved cardiac parameters also have 
been noted with this agent class in post infarction and in populations with advanced heart 
failure
(71)
. On the other hand, the use of thiazolidinediones in the management of patients with 
diabetic cardiomyopathy is problematic because of a propensity for fluid overload. In general, 
the choice of antidiabetic therapy in diabetic cardiomyopathy should be dictated by clinical 
characteristics,such as the presence or absence renal dysfunction, risk of hypoglycemia, age, 
volume status, and concomitant drug therapy. 
Neurohormonal Antagonism 
The important role of the renin-angiotensin-aldosterone system in the pathogenesis of 
complications in diabetic patients is well described. Evidence supports the use of Angiotensin- 
Converting Enzyme Inhibitors in preventing myocardial fibrosis, cardiac hypertrophy, and 
myocardial mechanical dysfunction associated with diabetic cardiomyopathy.
72-74
 Angiotensin-
converting enzyme inhibition and angiotensin-1 receptor blockade also have been shown to 
prevent coronary perivascular fibrosis and collagen deposition.
75
 The Angiotensin Receptor 
Blocker, candesartan, can improve echocardiographic parameters of diastolic dysfunction, 
reduce collagen synthesis, and increase collagen degradation in asymptomatic diabetic subjects.
76  
Novel Therapies Targeting Diabetic Cardiomyopathy 
Therapies directed toward the prevention and progression of diabetic cardiomyopathy are in the 
early stages of clinical development and have targeted either enhanced fibrosis/collagen 
deposition or alterations in cardiomyocyte metabolism.The majority of the agents listed below 
are in experimental stages, and none of them have been approved for use in diabetic 
cardiomyopathy. Notable among these novel agents are Advance Glycation End Product 
Inhibitors (eg,aminoguanidine, alanine aminotransferase 946, and pyridoxamine);Advance 
Glycation End Product Cross-Link Breakers (eg, alanine aminotransferase 711); and copper 
chelation therapy (eg, trientine). Modulators of free fatty acid metabolism,such as 
trimetazidine, have proven useful in the management of angina, but their efficacy on diabetic 
cardiomyopathy is unknown. Exenatide (recombinant glucagon-like peptide-1, a Food and Drug 
Administration-approved glucose-lowering agent) has yet to be studied specifically in patients 
with diabetic cardiomyopathy patients despite promising cardiac effects with glucagon-like 
peptide-1 infusion in mechanistic studies. 
MATERIALS AND METHODS 
 
 
The Clinical materials were  newly diagnosed  Type-2 Diabetes Mellitus  individuals selected 
from Diabetic outpatient department and the  department of internal medicine  in the Stanley 
hospital,Chennai-1 
 
About 77 patients were subjected to initial assessment , it included through clinical examination, 
routine blood investigation consisting  of  biochemistry investigation, ECG, estimation of HbA1c 
and echo cardiography were done from which 50 patients were included in the study and 
compared with 50 healthy age and sex matched controls. 
 
Informed consent was obtained from all the subjects and the hospital ethical board committee 
ethically approved the study. 
The Period of study was from march 2009 to September 2010. 
 
STUDY DESIGN – case control study 
 
STUDY GROUPS 
Group I - 50 newly diagnosed Type II Diabetes Mellitus patients. 
Group II - 50 healthy controls. 
These groups were selected on the basis of inclusion and exclusion criteria. 
 
 
 INCLUSION CRITERIA 
 Newly diagnosed Type II Diabetes Mellitus 
 Healthy controls 
 
EXCLUSION CRITERIA 
 Patients with age above 70 
 Systemic Hypertension. 
 conduction disturbance on ECG. 
 Documented Ischaemic heart disease 
 History suggestive of previous angina, congestive cardiac failure. 
 Documented evidence of other cardiac disease like cardiomyopathy 
 Valvular heart disease 
 Congenital Heart Disease 
 primary myocardial diseases, 
 pericardial diseases,  
 Chronic obstructive pulmonary disease 
 sustained arrhythmias   
 CKD  
 liver diseases  
 thyroid diseases  
 pregnancy and seriously ill patients     
      New cases were diagnosed by the revised criteria for diagnosis of diabetes mellitus.   
CRITERIA FOR DIAGNOSIS 
Revised criteria for diagnosing diabetes mellitus has been issued and taken from 
American Diabetes Association and the World Health Organization. 
The criteria is based on the premises that 
1. The spectrum of fasting plasma glucose (FPG) and the response to an oral glucose load 
varies in normal individuals. 
2. Diabetes Mellitus defined as the level of glycemia at which diabetic specific 
complications are noted and not on the level of glucose tolerance from a population based 
viewpoint. 
CRITERIA for Diagnosis of Diabetes
(6)  
1. HgbA1c of ≥ 6.5% is new diagnostic criterion. Needs to be done in a lab setting using 
NGSP certified method and following DCCT standard (point of care tests are not 
accepted) 
2. HgbA1C can not be used to diagnose diabetes in pregnancy nor in patients with anemia 
from iron deficiency or hemolysis Increased rate of red cell turnover 
3. Fasting Plasma Glucose > or = 126 (no calories for 8 hours) 
4. 2 hour plasma glucose > or = 200mg/dl using 75gm OGTT 
5. Random plasma glucose > or = 200 with hyperglycemia Symptoms 
 
Note: In the absence of unequivocal hyperglycemia and acute metabolic decompensation, these 
criteria should be confirmed by repeat testing on a different day. 
 
All of them were subjected to echocardiography done at the Department of Cardiology, Stanley 
hospital, Chennai. Echocardiograms were done using the commercially available Esaote`S My 
Lab50. which has the capabilities of performing two dimensional, M mode, Pulsed wave and 
continuous wave Doppler and colour flow imaging was used to obtain echo cardiogram images. 
Phased array transducers 2.5 - 3.5 MHz frequencies were used to obtain 2-D / M-mode echo 
cardiography. Images were obtained with subjects in 30 degree lateral decubitus position. All 
measurements were performed in the freezed images from all the patients, good quality images 
suitable for the measurements and interpretations were obtained and recorded. 
 
For assessment of LV systolic function the following parameters were calculated from the M- 
mode echocardiogram obtained at the level of mitral valve chordae. LV dimension diastole 
(LVId) systole (LVsd) and thickness of inter ventricular septum, left ventricular posterior wall 
thickness in diastole.LV ejection fraction was calculated using the following formula, 
EF= LVEDV-LDESV/ LVEDV x 100  
For the assessment of LV diastolic dysfunction following parameters were calculated from 
doppler transmitral flow velocities in the apical 4-chamber view by positioning the pulsed 
doppler sample volume between the tips of the mitral leaflets.   
1. LV filling during the early rapid phase(E wave m/s ), 
2. LV filling during atrial contraction (A wave m/s) 
3. Ratio of the filling velocity E/A ratio  
4. Deceleration time ( from the peak of E wave to the point at which the deceleration velocity 
reaches the base line) 
5. Isovolumetric relaxation time. (from the aortic valve closure to the beginning of E wave) 
  
STATISTICAL ANALYSIS 
All data were expressed as mean ± SD. Statistical analysis was performed using Graph pad 
Instat. Student`s T test were used between group comparison. Differences in variables between 
patients with and without LV diastolic dysfunction were analyzed using  Fisher’s Exact test and 
a P value of less than 0.05 was considered as statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATIONS AND RESULTS 
 
OBSERVATIONS  
Table No 1. SEX DISTRIBUTION 
Category 
Sex 
Total 
Female Male 
Diabetic  patients 32 18 50 
Controls 30 20 50 
 
Out of 50 patients in study group, 32 were female and 18 were male. In control 
group 30 were female and 20 were male.  
 
Table No. 2 AGE DISTRIBUTION 
 
 
Age(in 
Years) 
Control group Diabetic group 
Male Female Total % Male Female Total % 
31-40 4 4 8 16% 5 4 9 18% 
41-50 8 21 29 58% 7 22 29 58% 
51-60 5 3 8 16% 4 4 8 16% 
61-70 3 2 5 10% 2 2 4 8% 
 
More than half of the study population and control population belong to age group of 41-50 years 
(58%). 
SEX DISTRIBUTION 
  
 
AGE DISTRIBUTION IN DIABETIC PATIENTS 
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The Health Ministry has reduced the diagnostic cut-offs for body mass index (BMI) to 23 kg/m2 
and the standard waist circumference to assess obesity 
(77  )
 
            
Table No .3 DISTRIBUTION OF BMI IN DIABETIC GROUP 
 
Body Mass Index 
 
31-40 
years 
 
 
41-50 
years 
 
 
51-60 
years 
 
 
60-70 
years 
 
 
Total 
 
 
Percentage 
 
<18.5 Low BMI 0 1 1 0 2 4% 
18.6-23 healthy 6 7 2 1 16 32% 
23.1-25 Over wt 4 7 2 1 14 28% 
>25 obesity 0 13 3 2 18 36% 
 
   In study groups  4% were in low BMI 
                              32% were in healthy state 
                              28% were overweight  and  
                              36% were obese . 
        
             
 
 
 
Table No.4 DISTRIBUTION OF BMI IN CONTROL GROUP 
 
 Body mass index 
31-40 
years 
 
41-50 
years 
 
51-60 
years 
 
60-70 
years 
 
Total 
 
Percentag
e 
 
<18.5 Low 
BMI 
2 3 1 1 7 14% 
18.6-23 healthy 9 8 3 3 23 46% 
23.1-25 Over wt 4 8 1 2 15 30% 
>25 obesity 1 2 2 0 5 10% 
 
 
14% had low BMI, 46% had acceptable BMI, 30% had over weight and 10% had obesity  
In this study, obesity is more in diabetic population than control groups (36% vs.10%)  
 
 Unfavorable BMI was found in  32 patients out of 50(64%) 18 were overweight and 14 
were obese in diabetic group, where as in control group 20 people had un favorable BMI 
(40%) 15 were overweight and  5 were obese. 
 
 
 
 
 
 
Table No.5 Distribution of Waist Hip Ratio in study and control groups 
 
  
In study group 52% were in high risk. Females  (40%)  are more in high risk than male(12%).    
In control groups 20% were in high risk. Here also females (14%) are more in high risk than 
male(6%) . 
 
 
 
 
 
 
  
 
 
Waist hip ratio 
           
Male 
                  
Female 
≤0.95  
 low 
risk 
0.96-1  
moderate 
risk 
1.0+  
high 
risk 
≤0.80  
low 
risk 
0.81-0.85  
moderate 
risk 
0.85+  
high 
risk 
 
No of diabetic 
patients 
 
   8 
 
       4 
       
   6 
 
  4 
 
       8 
 
  20 
 
controls 
 
  14 
 
      3 
 
    3 
 
  12 
 
      9 
 
   7 
STATISTICAL ANALYSIS 
 
 
STUDY GROUP 
 
BMI mean value 
 
T value 
 
P value 
Total DM patients 
Total control 
25.396  ±  4.375 
22.012 ± 3.441 
 
4.298 
 
<0.0001 
Male patients 
Male control 
24.846  ±  4.949 
22.669  ±  4.116 
 
1.480 
 
0.1477 
Female patients 
Female control 
25.872  ± 4.089 
23.187  ±  3.948 
 
2.657 
 
0.010 
 
 
 
STUDY GROUP 
 
W/H ratio 
 
T value 
 
P value 
DM patients 
control 
0.9226 ± 0.1252 
0.8372  ± 0.0919 
 
3.887 
 
0.0002 
Male patients 
Male control 
0.9389  ±  0.1369 
0.8570  ± 0.1155 
 
1.999 
 
0.0532 
Female patients 
Female control 
0.9134  ± 0.1148 
0.8332  ±  0.0768 
 
3.353 
 
0.0013 
 
  
 Lipid analysis 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
The above statistical analysis showed significant correlation  between groups regarding the  Body 
Mass Index, Waist/Hip Ratio, Triglycerides, total cholesterol, HDL, and  LDL. 
 
Study 
group 
S.cholesterol T value P value 
Patients 205.08 ± 31.04 4.190 <0.0001 
control 178.90 ±  31.43 
Study group TGL T value P value 
patients 197.18±74.93 4.611 <0.0001 
control 142 ±  38.46 
Study group HDL T value P value 
patients 42.4±8.827 2.349 0.0208 
control 46.44 ± 8.367 
Study group LDL T value P value 
patients 124.26±32.47 4.289 <0.0001 
control 97.51 ± 29.82 
  
Table .6 COMPARISON OF CHARACTERISTICS BETWEEN SUBJECTS WITH 
NORMAL AND THOSE WITH DIASTOLIC DYSFUNCTION IN DIABETIC 
POPULATION 
 
 
 
  Variables  
                Diabetic patients  
T value 
 
P value With Normal  LV 
function(36) 
 with diastolic 
dysfunction(14) 
Age years 
Male :female 
BMI 
W/H ratio 
FBS 
PPBS 
HBA1C 
T.CHOLESTEROL 
TGL 
HDL 
LDL 
Urea 
S.Creatinine 
45.56 ± 7.16 
14:25 
24.48 ± 3.96 
0.907 ± 0.13 
163.28 ± 44.41 
261.81 ± 61.74 
8.13 ± 1.48 
197.75 ± 25.52 
179.17 ± 56.53 
43.97 ±8.5  
117.81 ± 26.9  
30.87±7.7 
0.74±3.8 
53.07 ± 8.76  
4:10 
27.18 ± 3.64 
0.963 ± 0.11 
187.5 ± 56.49 
316.86 ± 57.86 
 9.16 ± 1.4 
223.93 ± 36.72  
243.5 ± 97.03 
38.36 ± 8.65 
140.86 ± 40.20 
33.77±9.6 
0.79±4.3 
3.129 
 
2.205 
1.437 
1.603 
2.879 
2.250 
2.868 
2.927 
2.088 
2.356 
0.9740 
0.7645 
0.003 
 
0.0323 
0.1585 
0.1156 
0.0059 
0.0291 
0.0061 
0.0052 
0.0422 
0.0226 
0.3350 
0.2643 
ECHO variables 
IVS thickness 
LVPW thickness 
EF% 
 
10.36 ± 1.53 
9.26 ± 1.18 
57±8.2% 
 
11.61 ± 0.99 
10.75 ± 1.2 
58±6.8% 
 
2.806 
3.973 
0.762 
 
0.0072 
0.0002 
0.2613 
 
Baseline characteristics and laboratory data shows significant differences within diabetic group 
regarding the  Body Mass Index, Waist/Hip Ratio,  FBS, PPBS, Triglycerides, total cholesterol, 
HDL, and  LDL. No significant differences with respect to urea and creatinine concentrations 
were observed.  
Echocardiographic data are showed there were no significant differences within diabetic group 
regarding left ventricle ejection fraction, but there were significant differences in thickness of 
interventricular septum, thickness of left ventricle posterior wall. 
 
Table  No .7 TRANSMITRAL DOPPLER FLOW VELOCITY RECORDING 
 
Doppler 
parameter 
                 Diabetic  patients                       control 
Subjects with 
normal cardiac 
function  
Subject with 
diastolic 
dysfunction 
Subjects with 
normal cardiac 
function  
Subject with 
diastolic 
dysfunction 
Number 36(72%) 14(28%) 45(90%) 5(10%) 
E wave(cm/s) 71± 10 
 
56 ±10 
 
69± 11 
 
58 ± 12 
A wave(cm/s) 58 ±8 
 
71 ±3 
 
52 ±9 
 
69 ± 4 
E/A 1.26± 0.09 0.78 ±0.053 1.34± 0.17 0.81 ± 0.10 
DT(ms) 218 ± 46 244 ±51 189 ± 42 238 ± 48 
IVRT(ms) 106±19 110 ±11 90±17 109 ± 12 
 
Transmitral velocity data showed the significant low E/A ratio (E<A), prolonged declaration 
time (>240ms) and isovolumetric relaxation time (>110ms) in patients with diastolic dysfunction 
both in study group and control group.  
Table .8 GRADING OF DIASTOLIC DYSFUNCTION IN STUDY GROUPS 
Diastolic function 
category 
New diabetic 
patients 
Control group 
1.Normal pattern 
 
36 
 
45 
 
 
2.Impaired relaxation 
 
 
14 
 
 
5 
 
 
3.Pseudo normal pattern 
 
 
0 
 
 
0 
 
 
4.Restrictive pattern 
 
 
0 
 
 
0 
 
 
All of them had Grade I Diastolic dysfunction only. 
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Table No.9 INCIDENCE OF DIASTOLIC DYSFUNCTION IN STUDY GROUPS 
Study group With diastolic 
dysfunction 
Without diastolic 
dysfunction 
Total 
New diabetic 
patients 
14 36 50 
control 5 45 50 
 
Fisher`s exact test showed, the two- sided P value is 0.0395, and the Relative risk is 2.80  
considered statistically significant.  
Of the 50 patients of diabetic group that were included in the study, diastolic dysfunction was 
detected in 14 patients  giving an incidence of 28% .Where as in control group, out of 50 people 
5 had diastolic dysfunction giving an incidence of 10% , revealing a threefold risk in the 
incidence of diastolic dysfunction in newly diagnosed diabetic patients. 
 
Table No .10 DIASTOLIC DYSFUNCTION AND AGE DISTRIBUTION IN STUDY 
GROUPS 
Age Diastolic dysfunction 
New diabetic patients Control group 
40-50 7 0 
51-60 4 2 
61-70 3 3 
  
Diastolic dysfunction occurs more earlier in new diabetic patients than control population 50% in 
the age group of 40-50 years.  
 INCIDENCE OF DIASTOLIC DYSFUNCTION IN STUDY GROUPS 
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Table No. 11 GENDER DISTRIBUTION OF DIASTOLIC DYSFUNCTION 
 
In study groups, of the 32 females 10 patients(31.25%) had LVDD while of the 18 males 4 
patients had LVDD(22%).In  control groups, of the 30 females 3 person(10%) had LVDD  while 
of the 20 males 2 person  had LVDD(10%) 
GENDER DISTRIBUTION OF DD IN STUDY GROUPS 
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male 
 
14 
 
4 
 
18 
 
2 
 
female 
 
22 
 
10 
 
27 
 
3 
Table .12 ANALYSIS OF ASSOCIATED RISK FACTORS IN NEW DIABETIC 
PATIENTS WITH DIASTOLIC DYSFUNCTION 
Total BMI>25 
WHR 
>1/>.85 
FBS>200 PPBS>300 
HbA1C 
> 9 
T. chol 
> 240 
TGL 
>200 
HDL 
<40 
LDL 
>30 
14 8 7 5 9 6 4 8 8 5 
 
Out of 14 patients, 4 were male and 10 of them were female. 73% were obese, 64 % had higher 
waist-hip ratio, 45.46% had FBS >200, 82% had post prandial glucose >300 mg%, 57% had 
HbA1C > 9% and >50% had dyslipidemia. 
 
Table .13 ANALYSIS OF ASSOCIATED RISK FACTORS IN CONTROL GROUP WITH 
DIASTOLIC DYSFUNCTION 
Total BMI>25 
WHR 
>1/>.85 
T. Chol> 240 
TGL 
>200 
HDL <40 LDL >30 
5 1 3 0 1 2 1 
 
Out of 5 patients, 2 were male and 3 of them were female. 
Compared to the patients with diastolic dysfunction in control group, new diabetic patients with 
diastolic dysfunction had significantly higher BMI and dyslipidemia.  
In new diabetic patient, those who are having high PPBS at the time of diagnosis had significant 
correlation with diastolic dysfunction (P  value 0.0059) . 
 
 
 
 
DISCUSSION 
 
Epidemiological data indicate a greater risk of cardiovascular morbidity and mortality, 
particularly congestive cardiac failure, in diabetic subjects as compared with those without 
diabetes 
(78
).  The prevalence of diastolic dysfunction in diabetic population ranges from 30% to 
70%. 
Left ventricular diastolic dysfunction may represent the first stage of diabetic cardiomyopathy 
reinforcing the importance of early examination of diastolic function in individuals with 
diabetes. 
Our study showed that the prevalence of diastolic dysfunction in  newly diagnosed type 2 
diabetic patients was 28%  and those in control population it was 10% . 
Similar findings have been reported with Doppler echocardiography (E/A ratio), in newly 
diagnosed type 2 diabetic patients free of microvascular complications, without evidence of 
hypertension and coronary artery disease 
[79-81].
 
In the study of Gough et al
. [79]
LVdiastolic function was assessed with pulsed wave Doppler 
mitral flow velocities in20 normotensive patients with a new diagnosis of type 2 diabetes 
mellitus. The E/A ratio was significantly reduced in the diabetic group but despite improvements 
in glycemic control over 3 months (HbA1c 9.9% to 7.4%), maintained at 6 months (HbA1c 
7.0%), there were no changes in the E/A ratio. 
In the study of Beljic et al
. [80]
 LV diastolic function was evaluated at the onset of disease and 
after 6 and 12 months of adequate glycemic control. A significantly reduced value of peak E/A 
ratio was found in the diabetic patients before treatment, but did not significantly change after 1 
year of adequate glycemic control with therapy. 
Vanninen et al. 
[81]
 also demonstrated in a population of newly diagnosed diabetics,                  
an improvement of diastolic function concomitantly with declining blood glucose levels 
evaluated after a 15-month period. Of note, this was demonstrated with a complex 
echocardiographic indices but not with the conventional mitral E/A ratio. 
 
Di Bonito et al
. [82]
 reached to the same conclusions in a case-control study using Doppler 
echocardiography (E/A ratio). They observed diastolic dysfunction in 16 normotensive type 2 
diabetic patients, free of microvascular complications with a disease duration of less than 1 year. 
 
These observations of an impaired diastolic function in patients with newly diagnosed diabetes 
or with a short duration of the disease and with no microangiopathic complications suggest that 
this alteration may occur early in the history of type 2 diabetes and would not be related to 
microvascular complications. 
 
Celentano et al. 
[83]
 studied 64 subjects with normal glucose tolerance (n = 25), with impaired 
glucose tolerance (n = 15) and with type 2 diabetes mellitus (n = 24) diagnosed by an oral 
glucose tolerance test according to the recommendations of the World Health Organization. They 
found early signs of diastolic dysfunction (assessed by E/A mitral flow ratio), not only in patients 
with diabetes but also in those with impaired glucose tolerance, independent of the confounding 
role of ischemia, body weight, and blood pressure. 
 
Poirier et al
(84)
 in 2001 in Canada attempted to determine the prevalence of left ventricular 
diastolic dysfunction in middle-aged asymptomatic subjects with type 2 diabetes in a study, 
which included 46 men who has no evidence of diabetic complications, hypertension, coronary 
artery disease, congestive cardiac failure, thyroid or renal disease. Left ventricular diastolic 
dysfunction was found in 28 (60%) subjects impaired relaxation.  
 
Bajraktari et al 
(85)
 in 2004 in Kosovo demonstrated that left ventricular diastolic dysfunction 
was present in 68.8% of asymptomatic type 2 diabetic patients as compared to 34.9% in the 
control group without diabetes which was due to the presence of asymptomatic diabetic 
cardiomyopathy which was present in the diabetic population. 
It was also noted that diastolic dysfunction is more common among diabetic women and they 
also had a more advanced form of diastolic dysfunction as compared to men 
In our study, 0f the 32 female patients 10 patients(31.25%) had LVDD while  of the18 male  4 patients(22%) had LVDD 
 In Framingham study also females out  numbered the males.The Strong Heart study by Devereuex and colleagues in 2000 also 
demonstrated that diastolic dysfunction is more prevalent in women than in men. 
(86
)
   
This could be due to hormonal changes that accompany after menopause. 
                
           
 
 
Risk Factors Associated with Left Ventricular Diastolic Dysfunction 
(87, 88) 
Hypertension and IHD are recognized as important risk factors for left ventricular (LV) diastolic 
dysfunction. Some studies have shown that diabetes itself may also be an independent risk factor 
for LV diastolic dysfunction.  
In our study post prandial blood sugar (PPBS)  and HbA1c significantly correlated with diastolic 
dysfunction 
Poirier and colleagues 
84 
also did not find any difference in the glycemic indices and concluded 
that fasting blood glucose levels did not correlate with the presence of diastolic dysfunction in 
type 2 diabetes. However, Holzmann and colleagues demonstrated that the presence of diastolic 
dysfunction is related to the concentrations of fasting blood glucose, post prandial blood glucose 
and HbA1c 
(89)
. 
 
BMI was higher in patients with DD (27.18 ± 3.64  vs. 24.48 ± 3.96 kg/m
2
; P  value of 0.0323) , 
it has direct correlation with LVDD. But WHR (waist hip ratio) not significantly correlate with 
diastolic dysfunction 
 
Diabetic patients who had abnormal lipid values had increased incidence of LVDD than who had 
normal lipid values, particularly total cholesterol and TGL with significant P value of  0.0052. 
 
 
The potential risk factors for the development of diastolic dysfunction in type 2 diabetics that 
were determined were; (a) age ≥45 years was associated with an almost three times higher risk 
for the development of diastolic dysfunction, (b) females had almost two times a higher risk for 
the development of diastolic dysfunction as compared with men, and (c) diabetic patients with 
high PPBS and high HbAIc  were higher risk of developing diastolic dysfunction (d)diabetic 
patients with high BMI and dyslipidemia  was associated with higher risk for the development of 
diastolic dysfunction 
 
STUDY LIMITATION  
The limitation of our study was that TMT was not performed thus the possibility of coronary 
artery disease could not be completely excluded however the absence of clinical, 
Electrocardiographic and Echocardiographic evidence makes it unlikely, and this study was done 
in  a small population.   
 
 
 
 
 
 
 
SUMMARY  
 Incidence of diabetes is more common in the age group of 41-50years  
 Incidence of diastolic dysfunction is higher in new type 2 diabetic patients than control 
group, (28% vs 10%)  with significant p value 0.039,  they are in three fold risk in 
developing DD than general population. 
 Systolic dysfunction was not found in any newly detected type 2 diabetic patients. 
 Patients with LV diastolic dysfunction were older than patients without LV diastolic 
 
            dysfunction in new diabetic patients.(53.07 ± 8.76 vs. 45.56  ± 7.16 years; P 0.003). 
 
 
 Diastolic dysfunction occur more earlier in diabetic patients (40-50years), compared to 
control group where diastolic dysfunction commonly occur in elderly people (60-70). 
 Diastolic dysfunction in new type 2 diabetic patients showed a higher incidence in female 
population compared to male (28% vs 22%).  Interestingly diastolic dysfunction occurs in 
later age group  in female than male (>50years vs >40 years).  
 Analysis  clearly showed that new diabetic patient with diastolic dysfunction  had 
significant association with PPBS,HbA1C, BMI and dyslipidemia. 
 
 
 
 
 CONCLUSIONS 
 The incidence of diastolic dysfunction was found significantly high in newly 
diagnosed type 2 diabetes mellitus patients as compared with non diabetic subjects.  
 Prevalence of diastolic diastolic dysfunction in new diabetic population has female 
preponderance in the ratio of 2:1 .  
 Among the type 2 diabetes patients, Advancing Age, abnormal BMI, PPBS, raised 
HbA1c, elevated Total Cholesterol and Triglyceride were significantly associated 
with diastolic dysfunction.  
 Hence all newly detected diabetes with these risk factors should be evaluated for 
cardiac function with echocardiography. 
 When definite therapeutic and prevention strategies have evolved, then it may 
become necessary and useful to screen all new diabetic patients for LV diastolic 
dysfunction with echocardiography. 
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PROFORMA 
1.Name  
2.Age 
3.Sex 
4.Educational status 
5.Occupation 
6.Family income/yr 
7.Address 
8.Hgt in cms 
9.Wgt in kg 
10.BMI(kg/m2) 
11.Waist-hip ratio 
12.Clinical presentation 
       Polyuria,  Polydipsia, wgt loss 
13 . other history  
14.Past history-SHT, CAD ,CVA, PT  
15.Personal history- Alcohol, Smoking 
16.Family history 
17.Menstural history-pre menopausal/post menopausal 
18.Diet history; veg/non veg 
              Frequency/duration 
19.General examination; consciousness /orientation 
        Vitals   BP:                   PR:      
20. Systemic examination 
       CVS: 
       RS: 
       Abdomen;  
       CNS: 
21.investigations 
1.Urine R/E; Alb 
                           Sugar 
                           Deposits 
2.FBS 
    PPBS 
3.HbA1c 
4.Lipid profile 
5.ECG  
6 Eehocardiography 
           LV  IVS thickness/post wall thickness/LV diameter 
                 E/A ratio 
              Ejection fraction  
 
 
 
 
 
 
 
 
 
 INFORMED CONSENT FORM 
 
I agree to participate in the study titled ― ECHOCARDIOGRAPHIC EVALUATION OF 
CARDIAC FUNCTION IN NEWLY DETECTED TYPE 2 DIABETES PATIENTS‖ 
I confirm that I have been told in my mother tongue and have had the opportunity to ask 
questions 
I understand that my participation is voluntary and I may refuse to participate at any time without 
giving any reason and without affecting my benefits 
I agree not to restrict the use of any data or results that arise from this study 
 
 
Name of the participant: 
Signature/ thumb print: 
 
 
                          Witness                                                                   Investigator 
 
 
 
 
 
 
ABBREVIATIONS 
 
DM  Diabetes Mellitus 
CVD  Cardiovascular disease 
LVDF  Left ventricular diastolic function 
LVDD  Left ventricular diastolic dysfunction 
IDDM  Insulin dependent diabetes mellitus 
MODY Maturity onset diabetes of young 
BMI  Body mass index 
WHR  Waist hip ratio 
IFG  Impaired fasting glucose 
IGT  Impaired glucose tolerance 
HF  Heart failure 
AGE  Advanced glycation end products 
ROS  Reactive oxygen species 
FA  Fatty acid 
DT  Deceleration time 
IVRT  Isovolumetric relaxation time 
EF  Ejection fraction 
LVEDV Left ventricular end diastolic volume 
LDESV Left ventricular end systolic volume 
IVS  Interventricular septum 
LVPW  Left ventricular posterior wall 
MASTER CHART 
NEWLY DETECTED DIABETIC PATIENTS 
S.N name age sex BMI WHR BP FBS PPBS HbAIC TC TGL HDL LDL IVS LVPW E/A ratio EF% 
1 RAMALINGAM 57 M 24.89 1.08 130/80 152 247 7.7 200 150 42 110 8.2 8.7 1.3 63% 
2 LAKSHMI 65 F 23.8 0.84 128/86 163 370 9.6 261 280 35 191 13 11.2 0.86 60% 
3 GOWRI 50 F 23.58 0.87 136/86 134 228 7.2 176 180 56 86 9.8 10.8 1.1 62% 
4 SABIR ALLAH 47 M 20.06 0.82 120/78 135 248 7.2 179 175 45 94 11 12 1.1 58% 
5 SHANTHI 50 F 31.2 1.01 120/82 360 480 13.4 246 387 32 156 11.8 9.6 0.74 63% 
6 POWNU 56 F 24.09 0.74 132/84 133 210 7 210 207 38 130 9.8 10 1.2 68% 
7 LAKSHMI 45 F 31.11 1.06 120/80 128 198 6.8 210 232 31 132 8.6 9.8 1.4 59% 
8 PARIMALA 45 F 22.51 0.72 130/70 134 221 7.1 180 156 58 89 9.8 11 1.2 55% 
9 ISMAIL 64 M 23.59 1.12 126/78 162 288 9.2 230 366 36 138 10.8 9.8 0.79 64% 
10 PONNUTHAI 48 F 30.54 1.04 130/80 140 210 7.1 190 173 56 99 11.8 9.5 1.3 64% 
11 POOMARI 45 F 31.58 1.02 110/76 201 330 9.6 210 176 42 132 12.8 9.7 1.3 63% 
12 LOKESH 35 M 22.35 0.8 120/70 138 224 7.1 187 177 50 101 13 8.9 1.2 66% 
13 VENDRA 57 F 26.26 0.81 110/80 140 280 8.1 230 215 33 110 12.8 11.2 0.84 58% 
14 KALYANI 45 F 22.41 0.86 124/68 168 330 9.1 198 178 46 130 11.8 11 0.78 60% 
15 KASTHURI 55 F 21.93 0.88 110/70 160 276 8.3 261 206 35 190 9.6 11 1.3 61% 
16 RAJAMMAL 50 F 33.29 1.1 130/70 120 192 6.6 190 168 50 100 8.2 9.9 1.3 55% 
17 KAMALA 70 F 24.51 1.08 140/80 146 306 8.6 223 188 25 165 10.8 11.2 0.69 68% 
18 SUMATHI 37 F 22.67 0.89 120/80 200 320 9.5 186 166 50 99 10 9.8 1.2 69% 
19 THAMBIAYYAN 39 M 22.26 0.98 110/68 164 246 7.9 220 184 38 124 8.2 8.5 1.3 59% 
20 RAMANI 56 F 23.49 0.84 140/82 160 278 8.3 187 177 54 88 12 13 0.82 58% 
21 RAJENDRAN 44 M 24.89 0.81 130/78 180 240 8.1 210 344 42 168 9.8 7.4 1.4 64% 
22 SAVITHRI 48 F 23.8 0.84 126/86 180 268 8.5 210 190 46 130 10.2 8.9 0.74 59% 
23 GAJALAXMI 43 F 23.58 0.87 100/70 120 250 7.4 210 176 42 132 12.6 9.2 1.2 66% 
24 SAKAYAM 51 M 31.2 1.01 110/84 220 310 9.6 188 146 54 88 10.4 12 0.73 60% 
25 MUNI VEL 68 M 20.76 0.82 130/78 160 310 8.7 211 219 33 125 8.8 11 1.3 64% 
 NEWLY DETECTED DIABETIC PATIENTS 
 
S.N name age Sex BMI WHR BP FBS PPBS HbAIC TC TGL HDL LDL IVS LVPW E/A ratio EF% 
26 ANJALAI 40 F 20.54 0.85 120/80 320 420 13 240 210 42 146 9.9 11 1.4 55% 
27 NEELA 47 F 32 0.97 124/76 280 430 12 246 212 30 180 8.4 7.7 1.3 63% 
28 LAKSHMI 48 F 24.74 1.14 110/88 140 220 7.2 190 168 52 100 12.3 9.6 1.2 58% 
29 PATTU 50 F 27 0.94 134/78 210 320 9.6 183 166 54 98 13.4 10 1.3 59% 
30 KULANDAIRAJ 34 M 20 0.97 126/68 138 288 8.1 190 180 56 97 11.4 8.2 1.2 68% 
31 PANDIDURAI 42 M 28 0.98 130/80 168 246 8 200 246 38 130 13 11 0.86 58% 
32 PECHIAMMAL 34 F 24.16 1.02 120/80 126 188 6.6 175 120 25 126 10.6 10 1.3 60% 
33 VIJAYA 46 F 24.5 0.9 100/70 164 268 8.2 180 146 42 100 11 9 1.3 58% 
34 MEENAKSHI 38 F 24 0.86 136/84 204 320 9.5 192 150 46 116 9.8 7.1 1.1 68% 
35 JOSEPH 38 M 24.16 0.79 120/80 146 248 7.7 160 120 50 82 9.6 9.2 1.4 64% 
36 MUTHU 44 F 28.12 0.97 122/78 168 310 8.9 320 466 32 212 10.6 8.8 0.78 63% 
37 THIRUMALAI 38 M 24 0.78 100/80 160 210 7.4 160 110 50 88 11 9.6 1.4 59% 
38 VEDHACHALAM 48 M 30.24 0.98 136/78 230 360 10.4 200 150 40 110 12.6 9.8 0.82 69% 
39 RAJAMANICKAM 43 M 20.77 1.06 100/68 128 189 6.6 224 168 55 136 11.4 8.1 1.4 65% 
40 RAJANGAM 50 F 16.36 0.72 128/72 210 340 9.9 190 150 46 120 13 9.1 1.2 59% 
41 MEENAMBAL 45 F 29.12 0.86 110/70 116 188 6.5 190 155 35 125 11.8 8.3 1.3 59% 
42 RAJALAKSHMI 58 F 30.54 1.04 124/78 208 320 8.2 250 210 34 206 11.8 11 0.72 65% 
43 SAVARIMUTHU 55 M 31.58 1.02 110/70 166 288 8.5 160 110 50 88 8.8 8.6 1.2 59% 
44 VARALAXMI 40 F 22.35 0.72 134/80 188 310 9.1 190 160 40 128 11 9.5 1.1 60% 
45 VASANTHA 45 F 26.26 0.81 110/70 126 244 7.4 175 120 46 90 10.2 7.9 1.2 68% 
46 SHANMUGAM 44 M 22.41 0.86 124/78 166 310 8.9 194 138 44 110 9.6 8.3 1.3 62% 
47 MUNIYANDI 51 M 21.93 1.24 100/70 210 298 9.2 224 322 30 152 11 8.1 1.2 59% 
48 ALAMELU 45 F 33.29 1.1 110/82 152 290 8.4 192 210 32 118 11 12 0.76 60% 
49 VALLI 45 F 24.56 0.86 136/78 155 208 7.4 256 336 36 148 8.5 7.4 1.4 64% 
50 JAMES 45 M 20.8 0.78 120/80 126 188 6.7 170 120 46 100 8.8 9.6 1.3 60% 
CONTROL GROUP 
 
S.N NAME FBS PPBS BMI WHR BP TC TGL HDL LDL IVS LVPW E/A  EF 
1 SUMATHY 40/F 88 128 21.02 0.72 120/70 188 121 50 75.6 7.6 9.5 1.3 64% 
2 LAKSHMI 46/F 100 127 24 0.85 130/82 154 100 48 68 8.2 9.7 1.2 59% 
3 THAYANIDHI 50/M 96 121 23.12 0.79 140/88 190 176 51 104 8.6 7.1 1.1 55% 
4 RAJAMANI 45/M 117 129 32 0.82 132/86 164 110 56 86 8.2 9.2 1.2 58% 
5 PANDIAN 43/M 82 107 24.21 0.93 126/76 222 194 34 149 9.5 8.8 1.2 56% 
6 KANDASAMY 51/M 110 126 20.14 0.81 110/70 180 156 55 93.8 9.7 9.6 1.4 60% 
7 ANNAMANI 43/F 103 121 18.26 0.9 130/80 185 189 40 138 8.9 9.8 1.3 58% 
8 DEVAKI 40/F 112 127 24 0.72 120/80 140 118 60 56 9.2 8.1 1.3 65% 
9 KRISHNAN 42/M 88 112 23.44 0.86 134/86 136 96 62 54 7.8 9.1 1.4 62% 
10 RAMADEVI 54/F 82 118 31.5 1.01 140/80 271 200 36 110 11 9.8 0.74 64% 
11 MALLIGA 45/F 97 127 25.63 0.82 126/78 210 188 38 134 9.9 11 1.2 59% 
12 PARAMESWARI 38/F 90 126 23.3 0.82 110/70 158 116 60 78 11.2 8.6 1.3 64% 
13 VASUDEVAN 37/M 78 118 28.04 1.27 100/70 164 125 55 84 9.8 9.5 1.4 58% 
14 KANNAPPAN  68/M 98 134 23.87 0.79 140/86 240 190 32 130 10.8 12 0.82 56% 
15 UMAIYAL 62/F 115 136 18.74 0.76 134/78 130 120 56 68 7.8 8.3 1.3 64% 
16 SATHYA 47/F 99 113 24.12 0.83 120/80 202 180 44 153 7.4 8.1 1.2 60% 
17 SELVAMUTHU 44/M 108 127 20 0.78 124/82 175 160 54 89 8.9 8.5 1.3 62% 
18 MEERABAI 55/F 115 126 24 0.79 110/70 128 100 55 52 9.2 7.4 1.3 64% 
19 CHANDRAN 48/M 113 129 25.33 0.84 120/80 120 103 58 41 8.4 8.6 1.2 68% 
20 POOVATHAA 52/F 107 127 24.5 0.9 140/90 146 130 50 70 11 8.2 0.8 61% 
21 KAMALABAI 42/F 84 108 19.9 0.83 110/70 150 121 50 76 8.2 9.5 1.4 58% 
22 ANJALAI 50/F 100 128 24.8 0.86 130/80 102 90 48 36 11 9.7 1.3 59% 
23 ARUMUGAM 56/M 96 121 16.5 0.77 120/76 190 176 51 103 10 8.9 1.2 68% 
24 KADHAR 49/M 82 107 20 0.78 132/76 222 195 34 149 9 9.2 1.3 61% 
25 CHEZHIYAN 34/M 117 129 21 0.77 120/80 164 109 56 86 7.1 7.8 1.2 63% 
 
 
CONTROL GROUP 
 
S.N NAME FBS PPBS BMI WHR BP TC TGL HDL LDL IVS LVPW E/A  EF 
26 IRRUSAPPAN 70/M 70 118 17.14 0.93 130/80 196 138 38 100 9.2 11 1.3 60% 
27 SURYA DEVI 54/F 115 136 21.05 0.7 124/78 210 168 40 120 8.8 9.9 1.3 64% 
28 SHANMUGAVEL 62/M 99 113 18.73 0.76 140/86 190 134 46 100 9.6 11.2 0.75 59% 
29 MANSRANI 40/F 108 127 20.77 0.76 134/78 210 148 43 110 9.8 9.8 1.3 65% 
30 RAMASAMY 53/M 115 126 20 0.84 120/80 200 132 40 100 8.1 8.5 1.1 58% 
31 RAJENDRAN 53/M 113 129 24.16 0.91 124/82 198 136 42 90 9.1 8.9 1.4 62% 
32 PADMA 39/F 107 127 17.34 0.84 110/70 190 118 38 130 8.3 9.2 1.2 60% 
33 YOGALAKSHMI 37/F 92 128 16.5 0.77 120/80 184 140 44 112 11 8.4 1.2 58% 
34 SELVI 38/F 100 166 20.12 0.92 140/90 196 152 42 120 8.6 11 1.1 63% 
35 MARIAMMAL 40/F 102 134 21.05 0.8 110/70 188 138 46 90 9.5 8.2 1.4 62% 
36 DEVIKA 61/F 86 127 24.12 0.88 120/70 230 188 36 140 9.8 11 0.94 64% 
37 MARIYAAL 34/F 98 133 23 0.76 130/82 190 144 42 110 8.3 10 1.2 59% 
38 ABIRAMI 50/F 105 150 17.72 0.88 140/88 128 105 48 98 8.1 9 1.2 64% 
39 CHAKKUBAI 50/F 78 108 22 0.85 132/86 188 143 56 100 8.5 7.1 1.1 58% 
40 NATARAJAN 38/M 110 154 20.12 0.78 126/76 175 100 40 88 7.4 9.2 1.4 56% 
41 LATHA 43/F 94 100 20.5 0.86 110/70 134 98 56 54 9.6 8.8 1.2 64% 
42 ARUMUGAM 50/M 82 118 18 0.89 130/80 164 110 45 78 8.7 9.6 1.3 61% 
43 VALLIAMMAL 46/F 97 127 24.21 0.8 120/80 220 188 34 130 9.8 9.8 1.3 62% 
44 SUKUMAR 39/M 90 126 26 0.97 134/86 196 156 32 140 10.8 8.1 1.4 62% 
45 RAJANGAM 40/F 78 118 19.12 0.86 140/80 180 134 42 100 7.2 7.6 1.2 61% 
46 MEENAMBAL 42/F 98 134 21 0.7 126/78 188 121 50 75.6 9.6 8.2 1.3 60% 
47 RAJALAKSHMI 40/F 115 136 23.23 0.79 110/70 154 100 48 68 8.1 8.6 1.3 64% 
48 SAVARIMUTHU 55/M 99 113 21.18 0.85 122/86 190 176 51 104 9.8 8.2 1.4 67% 
49 VARALAXMI 40/F 78 118 17.12 0.82 130/70 164 110 56 86 11 9.5 1.2 62% 
50 VASANTHA 45/F 98 128 25 0.92 110/70 222 194 34 149 8.2 9.7 1.3 59% 
